To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop ...

a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in ...

Fermion and Simcere Pharma ink partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4: Guangzhou, China Monday, January 20, 2025, 11:00 Hrs [IST] ...

and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to ...

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to ...

Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D, and houses a "State Key Laboratory of Neurology and Oncology Drug Development".